Blog

  • Spirit Airlines shut down. Here’s what travelers need to know if they have tickets

    What travelers who are ticketed on Spirit Airlines need to know. Orijinal Kaynak

  • Berkshire Hathaway’s shopping extravaganza draws lighter crowds as spotlight shifts to Greg Abel

    Greg Abel made a point of stopping by every booth in the hall, greeting employees and shaking hands with shareholders. Orijinal Kaynak

  • Network shakeups hit Medicare Advantage, forcing retirees to pay up or find new care

    Network shakeups hit Medicare Advantage, forcing retirees to pay up or find new care

    Millions of Americans lose their Medicare Advantage plans each year, or their plan’s network changes and their doctors and hospital systems are no longer covered.

    Breakups are on the rise as hospitals and physician groups grow increasingly exasperated with insurance companies blocking medical care through preauthorizations and other red tape. At the same time, some insurers are jettisoning plans, hospital systems, and doctors.

    A prime example: UnitedHealthcare (UNH) and Johns Hopkins Medicine ended their network contract in August. That meant most Johns Hopkins facilities and providers became out of network for patients with UnitedHealthcare Medicare Advantage plans.

    For Medicare Advantage enrollees caught in the fray, it can be an expensive bad dream. When your long-standing doctor or preferred hospital is no longer covered by your insurance plan, for example, you’re considered out of network.

    That means you’re seeing a healthcare provider or receiving services at a medical center that doesn’t have an agreement with your health insurance plan to pick up most, if not all, of the bill. The upshot for you: Pay the steep out-of-pocket costs, or find a new provider.

    Proposed rule abandoned

    Last fall, the Centers for Medicare & Medicaid Services (CMS) issued a proposed rule that would revise the process for Medicare Advantage enrollees who experience midyear provider network changes, according to a CMS fact sheet.

    When providers and insurers split up, CMS reportedly gives enrollees a “special enrollment period” to change plans or enroll in traditional Medicare midyear. But how that works has been unclear and confusing. That prompted the proposed provision to make it easier.

    Now CMS has dropped the proposal, which would have taken effect in 2027.

    “We were disappointed that CMS did not finalize the provision to help more MA enrollees impacted by midyear network changes keep their doctor,” Lindsey Copeland, director of federal policy at the Medicare Rights Center, told Yahoo Finance.

    “Abruptly losing access to a trusted provider is a difficult experience, especially for people with complex or serious conditions,” she said.

    Maskot via Getty Images

    Medicare vs. Medicare Advantage

    Medicare Advantage is an alternative health insurance program to traditional Medicare for those ages 65 and older. The plans are run by private insurance companies and cover benefits not included in traditional Medicare, such as drug coverage (Part D), eyeglasses, dental care, and fitness classes. Plus, they typically have very low or even no premium costs.

    There’s a flip side. Unlike original Medicare, depending on the Advantage plan, you’re limited to a specific network of doctors and other healthcare providers, and those networks are ever-changing.

    Orijinal Kaynak

  • Weight loss and hair loss: The growing hair treatment market from GLP-1s

    Key Points
    • A common side effect of many GLP-1 drugs is hair loss. It’s creating a growing market for hair treatment products.
    • Companies like Redken, Nutrafol and KeraFactor are leaning into the innovation and marketing in that space, and retailers like Ulta are seeing more demand from customers.
    • Experts say the convergence of health, wellness and beauty poses an attractive opportunity for investors to buy in to the market.

    How GLP-1s are helping the hair care industry

    VIDEO3:1503:15
    How GLP-1s are helping the hair care industry

    When Branneisha Cooper first began taking GLP-1 injection Mounjaro in late 2022, she heard online that she could experience temporary hair thinning and prepared for the worst.

    But it would take about a year before she began noticing her hair falling out in clumps. Cooper said it was especially shocking because she has always had thick hair.

    “I was really hoping it wouldn’t happen,” Cooper, 29, told CNBC. “What my provider had told me is that since you’re on the medication that’s allowed you to lose weight at a faster rate, that’s what can cause hair loss.”

    Desperate to counteract the side effect, Cooper said she began prioritizing protein in her diet, taking vitamins intended to help her hair and investing in haircare products meant to stimulate the scalp to foster growth.

    She’s one of a growing number of GLP-1 users experiencing temporary hair loss from the drugs, creating a new market for hair treatment products amid the weight-loss drug craze.

    Cooper took to social media for support, where she found scores of other GLP-1 users experiencing the same thing. While the discourse was less frequent at the beginning of her weight-loss journey, the rise of GLP-1s has meant that more people are flocking to her page to commiserate and strategize.

    “There has been an increase of people wanting to know how to tackle it, but it’s also a lot of people who are wanting to know how they can possibly prevent it, and that’s just something that I don’t have the answer to,” Cooper said.

    According to Gallup, the use of GLP-1 drugs has more than doubled since early 2024. The KFF Health Tracking Poll found that roughly one in every eight U.S. adults, or nearly 13%, are currently taking a GLP-1 drug.

    By 2030, JPMorgan estimates that roughly 25 million Americans will be on a GLP-1, up from just 5 million in 2023.

    Profit amid loss

    Many GLP-1 users have seen significant results in losing weight. But the drugs come with a multitude of side effects, too.

    Zepbound, manufactured by pharmaceutical giant Eli Lilly, advertises common side effects on its website that include hair loss, nausea and vomiting, fatigue and more. Mounjaro, also a Lilly drug, warns of similar side effects, along with Novo Nordisk‘s Ozempic. Wegovy also includes hair loss in its possible side effects.

    It’s a risk that’s common with any type of significant weight loss because of the body’s changes, according to Dr. Heather Woolery-Lloyd, a dermatologist and the chief medical advisor for haircare brand Nutrafol.

    “When you are losing weight, either through a GLP-1 or any other type of weight loss, you may be taking in less nutrients, less protein, and the weight loss itself can be a stressor,” she told CNBC.

    Those consumers have been increasingly seeking out solutions to ease the physical process, according to Circana. The Chicago-based market research firm estimates that GLP-1 households spend approximately 30% more on beauty products than non-GLP-1 households.

    “Hair loss solutions continue to be a standout growth segment in hair care, sustained by prolonged consumer stress since the pandemic and GLP‑1 medication usage emerging as an incremental tailwind,” said Larissa Jensen, Circana’s beauty industry advisor. “Many GLP‑1 users report temporary hair shedding, which is translating into increased demand for at‑home growth treatments, scalp serums, and supplements.”

    The hit to a GLP-1 user’s self-confidence from the hair loss can mean even more stress, according to Woolery-Lloyd.

    In her practice, she said she’s seen a noticeable increase in patients coming in specifically with hair thinning concerns, many of them because of GLP-1 side effects. Woolery-Lloyd said the last time she saw an influx of patients with these concerns was during the pandemic, due to unexpected amounts of stress on the body.

    The hair loss from GLP-1s is one of the most significant side effects that the beauty industry is watching, according to Audrey Depraeter-Montacel, Accenture’s global beauty industry lead.

    “GLP-1s have not just changed the way people lose weight, but the way consumers expect beauty and personal care to address the situation,” she told CNBC, adding that it’s not a “one size fits all” solution.

    Depraeter-Montacel called the size of the GLP-1 market “unprecedented” and said the business opportunity for the hair treatment market with this growing population sets the scene for innovation.

    “On the life science side, we are seeing a lot of pharma brands raising funds to go after innovation and new solutions,” she said. “So a lot of money has been raised in the name of this opportunity, which I think confirmed that there is definitely a commercial opportunity here as investors put dollars in this on both sides.”

    Consumers who will be buying into the GLP-1 hair treatment market are also sticking around, Depraeter-Montacel said. Because hair treatment products often take a few months to begin showing results, these customers are expected to be highly loyal.

    Tapping into the market

    Brands are taking notice. In early April, Ulta CEO Kecia Steelman told Yahoo Finance that the company is seeing more consumers buying hair treatment products as part of the GLP-1 craze.

    Redken, a haircare company owned by L’Oreal, created an entire hair treatment line specifically for consumers with thin hair called the Acidic Grow Full System.

    “We wanted to ensure the Acidic Grow Full System range was tested on this specific population of GLP-1 users, as they may have unique hair care needs,” Mounia Tahiri, Redken’s U.S. general manager, told CNBC. “[It] was tested on current GLP-1 users who, when using the products, immediately noticed their hair looked fuller and felt thicker.”

    Tahiri said the company also saw a rise in Google searches for hair loss and weight-loss drugs and plans to continue innovating its hair treatment products as the GLP-1 population grows.

    Nutrafol CEO Cindy Gustafson told CNBC the haircare brand is similarly seeing increased demand for hair health products.

    “While we don’t break out performance tied to GLP-1 use, growth overall is being driven by increased awareness and a shift toward personalized, clinically supported solutions,” she said.

    Gustafson said the company expects this growth to continue as more people begin taking GLP-1s and searching for products to prevent or counteract hair thinning.

    KeraFactor, another scalp health company, told CNBC that it’s seeing 100% growth year-over-year in its direct-to-consumer store because of an increased interest from GLP-1 users.

    “We saw a lot of [hair loss] during Covid, so that was actually the first kind of spike of patients that came to KeraFactor, and then after Covid, it kind of settled,” Lauren Bartholomeusz, the company’s chief commercial officer, told CNBC. “And then now, we’re seeing that rise again with the GLP-1 craze.”

    Bartholomeusz said KeraFactor has shifted the way it treats patients to now come from a more preventative perspective to get ahead of the possible hair loss while taking the drugs.

    For Cooper, the 29-year-old GLP-1 user, there may be light at the end of the tunnel.

    She’s experimented with many hair products over the past three years of taking weight-loss drugs, hoping for her hair to return to its former thickness.

    “I’ve been paying more attention to it for about a year, and I’ve been noticing it’s returned,” Cooper said. “A lot of people, they get nervous when they have the hair shedding, because it’s like, ‘Oh, I’m going to be bald for eternity.’ But the hair comes back, so that was what let me have peace with it. But it was scary.”

    Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.

    Orijinal Kaynak

  • JPMorgan’s Jamie Dimon issued vague credit recession warning, but the bond market has more pressing issues

    Key Points
    • With Kevin Warsh expected to become the next Fed chair, markets will start to price in how new leadership could shift the path of rates, inflation policy, and future cuts.
    • Many investors remain more focused on stocks, but bonds may react first through changes in treasury yields, duration risk, and credit spreads, and some high-profile figures on Wall Street including JPMorgan CEO Jamie Dimon say the market be be overdue for a credit crisis.
    • Inflation is still above the Federal Reserve’s 2% target, while rates remain steady between 3.5% – 3.75% after this week’s FOMC meeting, but complacency in fixed income portfolios could lead to renewed volatility.

    In this article

    Beyond Big Tech: ETF managers look to international assets for diversification

    VIDEO6:3206:32
    Beyond Big Tech: ETF managers look to international assets for diversification

    Risk in the credit markets has received a lot of attention in 2026, from fears about private credit stress to the head of the nation’s biggest bank, JPMorgan CEO Jamie Dimon, warning this week — though not pointing to any specific current credit market signal — “We haven’t had a credit recession in so long, so when we have one, it would be worse than people think. It might be terrible.” 

    Dimon isn’t the only Wall Street veteran worried about the longer-term outlook for the bond market. But as investors focus on the likely confirmation of a new Federal Reserve chair, Kevin Warsh, many may be overlooking a more short-term volatile reaction in store for fixed-income portfolios. Whenever there is a Fed transition, treasury yields, duration risk, and credit spreads usually move faster as the markets begin to reassess monetary policy.

    “What is really important over the next several weeks is this changing of the guard at the Fed chair level,” Paisley Nardini, Simplify Asset Management managing director and head of multi-asset solutions, said on the podcast portion of CNBC’s “ETF Edge” on Monday.

    Nardini explained that even when there is no immediate policy move, markets can start pricing in the future quickly. A new Fed chair can change the communications style and alter the pace of future rate hikes or cuts. She said this could send ripples through the treasury market before equities fully react.

    “I think the markets are really going to be cautious as to what this might mean. Anytime there is a changing of the guard, markets are going to experience some volatility and we are going to have to start to price in what that means,” she said.

    There was a lot of Fed news to digest this week. The Federal Reserve held interest rates steady at its meeting Wednesday, with the federal funds rate unchanged in a 3.50% to 3.75% range. But the war and the surge in oil prices has upended the policymaking assumptions of the central bank and bond traders, who are now betting against another rate cut in 2026. Fed Chair Jerome Powell said the added the pressure on the economy from higher oil prices is likely to remain, even if it hasn’t yet upended the longer-term inflation outlook.

    But there is more disagreement than ever inside the Fed, with a shift within the FOMC as more members say there should be no indication at all from the institution that the bias remains towards cutting rates. Chair Powell also said he has no intention to leave his position as Fed governor even when his term as chairman ends, further complicating an already heightened political environment at the Fed.

    This backdrop can make the bond market more sensitive, and inflation remains above target with the latest personal consumption expenditures index hovering around 3.5% annually. Core PCE rose to 3.2%.

    “If we remember the role of the Fed, we have a dual mandate and that is data driven. And so we have employment on one side of the spectrum and inflation on the other side,” Nardini said, referring to the goal of maximum employment for the economy and 2% inflation. “In a portfolio, often times we forget about bonds until it is front and center and it is too late to react or adjust your portfolio accordingly,” she said.

    There is reason to believe more investors may have chosen to ignore bonds during Powell’s tenure at the Fed: they’ve done terribly. The Bloomberg US Aggregate Bond Index that aims to track all U.S. investment-grade debt returned just under 2% annually during Powell’s tenure, far below the average of 6.5% since the 1970s, according to Bespoke. The era of higher interest rates due to inflation, with multiple shocks from Covid to Russia’s invasion of Ukraine and the current U.S.-Iran war, were causes.

    Nardini says with the Fed currently in hold mode, the first major risk for bond investors is duration. If investors are loaded up on longer-dated bonds and expecting cuts, they may be vulnerable if they arrive late or not at all. The 10-year treasury has already swung sharply this year, with its current yield over 4%.

    The second risk is credit strength. Nardini says corporate spreads remain relatively tight, meaning investors have not been paid significantly more for taking on additional risk in bonds beyond the risk-free treasuries rate. That dynamic can become more important late in the cycle if economic and credit weakness grow. “You really have to dissect how much of a yield within credit is coming from treasuries vs. that spread component,” she said.

    The historically tight levels for credit spreads, recently testing multi-decade lows, represents belief among investors that risk of default is low and the economic outlook is strong. But at the same time, even with a Fed on hold, markets had been increasing bets this year that the yield curve will steepen, as short-term rates remain more sensitive to an eventual Fed cut while longer-term rates confront prospects of sticky inflation and higher levels of public debt, a concern implicit in warnings like Dimon’s.

    Nardini says during periods of relative calm, it is important to remember that calm can be deceptive. “Anytime the markets get complacent, whether that is in equities or within bonds, that is usually when volatility strikes,” she said. 

    Sign up for our weekly newsletter that goes beyond the livestream, offering a closer look at the trends and figures shaping the ETF market.

    Disclaimer

    Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.

    Orijinal Kaynak